Program
GSK-3965193
In GlaxoSmithKline’s pipeline, PAPD5/PAPD7 inhibitor
. Its studies are mostly in Hepatitis B, Chronic, led by GlaxoSmithKline.
Furthest: phase 2, since Apr 8, 20221 company-led study, 0 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| GlaxoSmithKline | 10 open or running | phase 2since Apr 8, 2022 | Apr 8, 2022 | none ahead |
- Named in GlaxoSmithKline’s own pipeline as
GSK3965193
, phase 1, as of Sep 30, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 8, 2022First study: phase 2 study in Hepatitis BFirst studyNCT05330455 · 74 enrolled · Canada, France, Italy and more
TargetBeta
“PAPD5/PAPD7 inhibitor”the company's pipeline, read by Claude · source
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT05330455Hepatitis B · Canada, France, Italy and more | 2 | Terminated | May 19, 2025 | 74 |
How it is read
Names in the registry
- “GSK3965193”, 1 entry
Conditions, from the studies’ own filings
- Hepatitis B, Chronic, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.